Animal experiments on the enhancement of fibrinolytic potential by anabolic steroids.
In animal experiments the anabolic steroids 4-chloro-17 beta-hydroxy-17-methylandrosta-1,4-dien-3-one and 4-chloro-11 beta-hydroxy-17-methylandrosta-1,4-dien-3-one were tested for their ability to enhance fibrinolysis in comparison to stanozolol. After daily administration of 2 mg/kg for 12 weeks the anabolic steroids were found to enhance spontaneous fibrinolytic activity of blood, fibrinolytic capacity and tissue plasminogen activator activity in the kidneys of rats and rabbits. Concomitantly, the AT III activity of blood increased.
D000818:Animals; D000990:Antithrombin III / Q000378:metabolism; D005342:Fibrinolysis / Q000187:drug effects*; D007668:Kidney / Q000378:metabolism; D008168:Lung / Q000378:metabolism; D008297:Male; D008696:Methandrostenolone / Q000031:analogs & derivatives* / Q000494:pharmacology; D010960:Plasminogen Activators / Q000378:metabolism; D011817:Rabbits; D051381:Rats; D011919:Rats, Inbred Strains; D013197:Stanozolol / Q000494:pharmacology; D013739:Testosterone / Q000031:analogs & derivatives* / Q000494:pharmacology
C000430:D-4-chloro-17 beta-hydroxy-3-oxo-17 alpha-methylandrosta-1,4-diene; D013739:Testosterone; D013197:Stanozolol; D000990:Antithrombin III; C043022:4-chloro-11-hydroxy-17-methylandrosta-1,4-dien-3-one; D008696:Methandrostenolone; D010960:Plasminogen Activators